A CROSS-SECTIONAL STUDY TO DETERMINE THE OUTCOMES OF FAMILIAL AMYLOID POLYNEUROPATHY AND PSYCHOLOGICAL FACTORS
Keywords:
Familial amyloid polyneuropathy, Psychological factor, Quality of life, Symptoms, Mortality and morbidityAbstract
Background: Familial amyloid neuropathy (FAP) is a rare neurological disease that can be fatal and often leads to increased disability. Objective: The aim of this study was to assess and determine the clinical outcomes of patients with familial amyloid polyneuropathy in relation to psychological factors and quality of life. Patients and method: 72 patients with familial amyloid polyneuropathy who were between 20 and 50 years of age and had registered in the familial amyloid polyneuropathy survey were included in the study. This study used EQ-5D-3L scale assessments to evaluate psychological status as well as health-related quality of life. Results: Our study's outcomes shown that females had 43 cases that more than males with 29 cases of morbidity of familial amyloid polyneuropathy (FAP), where the most symptoms prevalent were tingling and numbness in the extremities included 22 cases, muscle weakness included 15 cases, and pain included 20 cases, Serum albumin level was 4.3 ± 0.38 g/dL, postural systolic blood pressure changes mean (SD), mm Hg was - 12.5 ± 17.6, which Disease stage based on polyneuropathy disability (PND) classified into I had 32 cases, II had 21 cases, IIIA had 11 cases, IIIB had 5 cases, and IV had 3 cases. Conclusion: The quality of life related to health in patients having familial amyloid neuropathy disorder is largely influenced by these signs and associated losses in capacities.
References
Andrade C. A peculiar form of peripheral neuropathy; familiar atypical, generalized amyloidosis with special involvement of the peripheral nerves. Brain. 1952;75 (3):408–27.
Schmidt HH, Waddington-Cruz M, Botteman MF, Carter JA, Chopra AS, Hopps M, et al. Estimating the global prevalence of transthyretin familial amyloid polyneuropathy. Muscle Nerve. 2018;57 (5):829–37.
Ines M, Coelho T, Conceicao I, Duarte-Ramos F, de Carvalho M, Costa J. Epidemiology of Transthyretin familial amyloid polyneuropathy in Portugal: A Nationwide study. Neuroepidemiology. 2018;51 (3–4):177–82.
Parman Y, Adams D, Obici L, Galan L, Guergueltcheva V, Suhr OB, et al. Sixty years of transthyretin familial amyloid polyneuropathy (TTR-FAP) in Europe: where are we now? A European network approach to defining the epidemiology and management patterns for TTR-FAP. Curr Opin Neurol. 2016;29 (Suppl 1): S3–S13.
Ando Y, Coelho T, Berk JL, Cruz MW, Ericzon BG, Ikeda S, et al. Guideline of transthyretin-related hereditary amyloidosis for clinicians. Orphanet J Rare Dis. 2013;8:31.
Coelho T, Ines M, Conceicao I, Soares M, de Carvalho M, Costa J. Natural history and survival in stage 1 Val30Met transthyretin familial amyloid polyneuropathy. Neurology. 2018;91 (21):e1999–2009.
Coutinho P, da Silva AM, Lima JL, Barbosa AR. Forty years of experience with type I amyloid neuropathy. Review of 483 cases. In: Glenner GG, Pinho e Costa P, de Freitas F, editors. Amyloid and Amyloidosis. Amsterdam: Excerpta Medica; 1980. p. 88–98.
Holmgren G, Steen L, Ekstedt J, Groth CG, Ericzon BG, Eriksson S, et al. Biochemical effect of liver transplantation in two Swedish patients with familial amyloidotic polyneuropathy (FAP-met30). Clin Genet. 1991;40 (3):242–6.
Holmgren G, Ericzon BG, Groth CG, Steen L, Suhr O, Andersen O, et al. Clinical improvement and amyloid regression after liver transplantation in hereditary transthyretin amyloidosis. Lancet. 1993;341 (8853):1113–6.
Benson MD. Liver transplantation and transthyretin amyloidosis. Muscle Nerve. 2013;47 (2):157–62.
Coelho T, Maia LF, Martins da Silva A, Waddington Cruz M, Plante Bordeneuve V, Lozeron P, et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology. 2012;79 (8):785–92.
Coelho T, Maia LF, da Silva AM, Cruz MW, Plante-Bordeneuve V, Suhr OB, et al. Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy. J Neurol. 2013;260 (11):2802–14.
Benson MD, Waddington-Cruz M, Berk JL, Polydefkis M, Dyck PJ, Wang AK, et al. Inotersen treatment for patients with hereditary Transthyretin amyloidosis. N Engl J Med. 2018;379 (1):22–31.
Adams D, Gonzalez-Duarte A, O'Riordan WD, Yang CC, Ueda M, Kristen AV, et al. Patisiran, an RNAi therapeutic for hereditary Transthyretin amyloidosis. N Engl J Med. 2018;379 (1):11–21.
Conceicao I, Gonzalez-Duarte A, Obici L, Schmidt HH, Simoneau D, Ong ML, et al. "Red-flag" symptom clusters in transthyretin familial amyloid polyneuropathy. J Peripher Nerv Syst. 2016;21 (1):5–9.
Adams D, Theaudin M, Cauquil C, Algalarrondo V, Slama M. FAP neuropathy and emerging treatments. Curr Neurol Neurosci Rep. 2014;14 (3):435.
Yarlas A, Gertz MA, Dasgupta NR, Obici L, Pollock M, Ackermann EJ, et al. Burden of hereditary transthyretin amyloidosis on quality of life. Muscle Nerve. 2019;60 (2):169–75.
Stewart M, Shaffer S, Murphy B, Loftus J, Alvir J, Cicchetti M, et al. Characterizing the high disease burden of Transthyretin amyloidosis for patients and caregivers. Neurol Ther. 2018;7 (2):349–64.
Jonsen E, Athlin E, Suhr OB. Family members' experience of familial amyloidotic polyneuropathy disease--an internal struggle and a fact of life. J Adv Nurs. 2000;31 (2):347–53.
Coelho T, Maurer MS, Suhr OB. THAOS - the Transthyretin amyloidosis outcomes survey: initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis. Curr Med Res Opin. 2013;29 (1):63–76.
Plante-Bordeneuve V, Suhr OB, Maurer MS, White B, Grogan DR, Coelho T. The Transthyretin amyloidosis outcomes survey (THAOS) registry: design and methodology. Curr Med Res Opin. 2013;29 (1):77–84.
Ferreira LN, Ferreira PL, Pereira LN, Oppe M. EQ-5D Portuguese population norms. Qual Life Res. 2014;23 (2):425–30.
EuroQol G. EuroQol--a new facility for the measurement of health-related quality of life. Health Policy. 1990;16 (3):199–208.
Dolan P. Modelling valuations for health states: the effect of duration. Health Policy. 1996;38 (3):189–203.
Ferreira LN, Ferreira PL, Pereira LN, Oppe M. The valuation of the EQ-5D in Portugal. Qual Life Res. 2014;23 (2):413–23.
Dyck PJ, Davies JL, Litchy WJ, O'Brien PC. Longitudinal assessment of diabetic polyneuropathy using a composite score in the Rochester diabetic neuropathy study cohort. Neurology. 1997;49 (1):229–39.
Auvin S, Irwin J, Abi-Aad P, Battersby A. The problem of rarity: estimation of prevalence in rare disease. Value Health. 2018;21 (5):501–7.
Ollendorf DA, Chapman RH, Pearson SD. Evaluating and valuing drugs for rare conditions: no easy answers. Value Health. 2018;21 (5):547–52.
Nestler-Parr S, Korchagina D, Toumi M, Pashos CL, Blanchette C, Molsen E, et al. Challenges in research and health technology assessment of rare disease technologies: report of the ISPOR rare disease special interest group. Value Health. 2018;21 (5):493–500.
Drummond MF, Wilson DA, Kanavos P, Ubel P, Rovira J. Assessing the economic challenges posed by orphan drugs. Int J Technol Assess Health Care. 2007;23 (1):36–42.
